MILFORD, Connecticut, May 8 /PRNewswire/ -- Impliant, Inc. (www.impliant.com), a developer of novel spine arthroplasty alternatives to fusion surgery, today announced that its wholly-owned subsidiary, Impliant, Ltd., has been awarded two United States patents for its spinal implant solutions in posterior motion preservation.
Ron Sacher, Chief Executive Officer of Impliant, said, "We are pleased that the United States Patent and Trademark Office has recognized the ingenuity of the TOPS(TM) System. These medical device patents are strategic assets for the Company as we continue to build our leadership position in the posterior spine motion preservation market with Impliant's Total Posterior Arthroplasty solution."
The first patent (U.S. Patent No. 6,966,930) is a minimally invasive facet repair system that allows surgeons to implant a spacer between the posterior joints of the spine. The spinal implant device is intended to alleviate isolated facet joint pain due to joint space narrowing-a degenerative spinal condition associated with facet arthrosis.
The second patent (U.S. Patent No. 7,011,685) is the basis for Impliant's TOPS(TM) System-a novel three-axes Total Posterior Arthroplasty solution. The TOPS(TM) System, an alternative to spinal fusion, is designed to stabilize but not fuse the affected vertebral level after a laminectomy and medial facetectomy to alleviate pain stemming from degenerative spondylolisthesis, spinal stenosis, and facet arthrosis.
Impliant has the longest series of patents for these broad posterior indications that have been successfully treated with a motion preservation device. The patented TOPS(TM) System is currently being investigated in leading centers around the world.
About the TOPS(TM) System
Impliant's TOPS(TM) System, a mobile posterior device, is designed to stabilize but not fuse the affected vertebral level to alleviate pain stemming from degenerative facet arthrosis, spondylolisthesis, and spinal stenosis. Following a laminectomy and medial facetectomy, the device is affixed to the spine via four pedicle screws using a standard posterior surgical approach. Impliant believes that the TOPS(TM) System could benefit 300,000 patients worldwide undergoing spinal fusion surgery each year. The TOPS(TM) System is not approved for sale or use in the United States.
About Impliant, Inc.
Impliant, Inc. is a privately held company engaged in the development of novel spine arthroplasty solutions. The company is currently developing the TOPS(TM) System, which is designed to alleviate pain resulting from degenerative facet arthrosis, spondylolisthesis, and spinal stenosis by stabilizing but not fusing the affected vertebral level. Impliant is headquartered in Milford, CT with research facilities located in Ramat Poleg, Israel. For more information about Impliant, please visit www.impliant.com.
Ron Sacher, CEO Todd Potokar, President